Inactive Instrument

Telik, Inc. Stock Nasdaq

US87959M1099

Biotechnology & Medical Research

End-of-day quote Nasdaq
- ^USD	-

20-03-20	MabVax Therapeutics Holdings, Inc. Went Out of Business	CI
20-03-05	Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc.	CI

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	1.11M 987K 921K 839K 1.58M 107M 1.6M 11.15M 4.32M 54.58M 4.17M 4.08M 175M	P/E 2016	-0.93x	P/E 2017	-0.25x
Enterprise Value	3.59M 3.19M 2.98M 2.71M 5.12M 345M 5.17M 36.05M 13.97M 177M 13.49M 13.19M 567M	EV / Sales 2016	147x	EV / Sales 2017	-
Free-Float	92.02%	Yield 2016 *	-	Yield 2017	-

20-03-20	MabVax Therapeutics Holdings, Inc. Went Out of Business	CI
20-03-05	Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc.	CI
20-01-10	Second Amended Liquidation Plan and Disclosure Statement Conditionally Approved for MabVax Therapeutics Holdings, Inc.	CI
20-01-08	Second Amended Combined Joint Liquidation Plan and Disclosure Statement Filed by MabVax Therapeutics Holdings, Inc.	CI
19-12-15	First Amended Combined Joint Liquidation Plan Filed by MabVax Therapeutics Holdings, Inc.	CI
19-11-27	Joint Liquidation Plan and Disclosure Statement Filed by MabVax Therapeutics Holdings, Inc.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For MabVax Therapeutics Holdings, Inc.	CI
19-07-29	Motion for Exclusivity Period Extension Approved For MabVax Therapeutics Holdings, Inc.	CI
19-07-10	First Motion for Exclusivity Period Extension Filed by MabVax Therapeutics Holdings, Inc.	CI
19-06-26	Motion for Asset Sale Approved for MabVax Therapeutics Holdings, Inc.	CI
19-06-12	Bankruptcy Judge Changed for MabVax Therapeutics Holdings, Inc.	CI
19-05-07	BioNTech Research and Development, Inc. completed the acquisition of substantially all assets from MabVax Therapeutics Holdings, Inc..	CI
19-05-07	Motion for Asset Sale Approved for MabVax Therapeutics Holdings, Inc.	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.23%	-0.59%	+52.63%	+128.54%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+56.96%	+138.26%

	2016	2017
Net sales	148K 132K 123K 112K 211K 14.23M 213K 1.49M 576K 7.28M 556K 544K 23.35M	-
Net income	-17.66M -15.69M -14.65M -13.35M -25.18M -1.7B -25.41M -177M -68.68M -868M -66.31M -64.87M -2.79B	-19.02M -16.9M -15.77M -14.38M -27.11M -1.83B -27.37M -191M -73.97M -935M -71.41M -69.86M -3B
Net Debt	470K 418K 390K 355K 670K 45.19M 676K 4.72M 1.83M 23.1M 1.77M 1.73M 74.15M	2.48M 2.2M 2.06M 1.88M 3.54M 239M 3.57M 24.9M 9.65M 122M 9.32M 9.11M 391M

Telik, Inc. Stock Nasdaq

Stocks

US87959M1099

Biotechnology & Medical Research

Valuation: Telik, Inc.

Latest news: Telik, Inc.

Managers and Directors: Telik, Inc.

Bio Therapeutic Drugs

Financials

Company Profile